Brain and other central nervous system tumor statistics, 2021.
Adolescent
Adult
Aged
Brain Neoplasms
/ classification
Central Nervous System Neoplasms
/ classification
Child
Child, Preschool
Female
Humans
Infant
Infant, Newborn
Male
Middle Aged
National Program of Cancer Registries
/ statistics & numerical data
Registries
/ statistics & numerical data
SEER Program
/ statistics & numerical data
United States
/ epidemiology
Young Adult
Central Brain Tumor Registry of the United States (CBTRUS)
brain tumors
central nervous system tumors
epidemiology
Journal
CA: a cancer journal for clinicians
ISSN: 1542-4863
Titre abrégé: CA Cancer J Clin
Pays: United States
ID NLM: 0370647
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
16
06
2021
accepted:
16
06
2021
pubmed:
25
8
2021
medline:
16
11
2021
entrez:
24
8
2021
Statut:
ppublish
Résumé
Brain and other central nervous system (CNS) tumors are among the most fatal cancers and account for substantial morbidity and mortality in the United States. Population-based data from the Central Brain Tumor Registry of the United States (a combined data set of the National Program of Cancer Registries [NPCR] and Surveillance, Epidemiology, and End Results [SEER] registries), NPCR, National Vital Statistics System and SEER program were analyzed to assess the contemporary burden of malignant and nonmalignant brain and other CNS tumors (hereafter brain) by histology, anatomic site, age, sex, and race/ethnicity. Malignant brain tumor incidence rates declined by 0.8% annually from 2008 to 2017 for all ages combined but increased 0.5% to 0.7% per year among children and adolescents. Malignant brain tumor incidence is highest in males and non-Hispanic White individuals, whereas the rates for nonmalignant tumors are highest in females and non-Hispanic Black individuals. Five-year relative survival for all malignant brain tumors combined increased between 1975 to 1977 and 2009 to 2015 from 23% to 36%, with larger gains among younger age groups. Less improvement among older age groups largely reflects a higher burden of glioblastoma, for which there have been few major advances in prevention, early detection, and treatment the past 4 decades. Specifically, 5-year glioblastoma survival only increased from 4% to 7% during the same time period. In addition, important survival disparities by race/ethnicity remain for childhood tumors, with the largest Black-White disparities for diffuse astrocytomas (75% vs 86% for patients diagnosed during 2009-2015) and embryonal tumors (59% vs 67%). Increased resources for the collection and reporting of timely consistent data are critical for advancing research to elucidate the causes of sex, age, and racial/ethnic differences in brain tumor occurrence, especially for rarer subtypes and among understudied populations.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
381-406Informations de copyright
© 2021 The Authors. CA: A Cancer Journal for Clinicians published by Wiley Periodicals LLC on behalf of American Cancer Society.
Références
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7-33.
Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017. Neuro Oncol. 2020;22(12 suppl 2):iv1-iv96.
107th Congress. Benign Brain Tumor Cancer Registries Amendment Act. 107 Cong Rec. §260 (2002). Accessed January 17, 2021. govinfo.gov/app/details/CREC-2002-08-01/CREC-2002-08-01-pt2-PgS8022-3
Central Brain Tumor Registry of the United States (CBTRUS). SEER*Stat Database. Centers for Disease Control and Prevention National Program of Cancer Registries and National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Incidence Data (1995-2017). CBTRUS; 2019.
National Program of Cancer Registries (NPCR). SEER*Stat Database: NPCR Survival Analytic File-2001-2016. US Department of Health and Human Services, Centers for Disease Control and Prevention; 2020.
Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER Research Data, 9 Registries, November 2019 Submission (1975-2017)-Linked To County Attributes-Time Dependent (1990-2017) Income/Rurality, 1969-2018 Counties. National Cancer Institute, Division of Cancer Control & Population Sciences, Surveillance Research Program; 2020.
Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Mortality-All COD, Aggregated With State, Total U.S. (1990-2018) [underlying mortality data provided by the National Center for Health Statistics]. National Cancer Institute, Division of Cancer Control & Population Sciences, Surveillance Research Program; 2020.
Fritz A, Percy C, Jack A, et al, eds. International Classification of Diseases for Oncology. 3rd ed. World Health Organization/International Agency for Research on Cancer; 2000. Accessed March 1, 2020. codes.iarc.fr/
Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International Classification of Childhood Cancer, third edition. Cancer. 2005;103:1457-1467.
Ostrom QT, Kruchko C, Barnholtz-Sloan JS. Pilocytic astrocytomas: where do they belong in cancer reporting? Neuro Oncol. 2020;22:298-300.
Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131:803-820.
World Health Organization. International Statistical Classification of Diseases and Related Health Problems (ICD). 10th Revision. World Health Organization; 2013. Accessed March 1, 2020. who.int/classifications/icd/en/
National Cancer Institute. Joinpoint Regression Program, Version 4.7.0.0. Statistical Methodology and Applications Branch, Surveillance Research Program, National Cancer Institute; 2019.
Ostrom QT, Adel Fahmideh M, Cote DJ, et al. Risk factors for childhood and adult primary brain tumors. Neuro Oncol. 2019;21:1357-1375.
Porter AB, Lachance DH, Johnson DR. Socioeconomic status and glioblastoma risk: a population-based analysis. Cancer Causes Control. 2015;26:179-185.
Cote DJ, Ostrom QT, Gittleman H, et al. Glioma incidence and survival variations by county-level socioeconomic measures. Cancer. 2019;125:3390-3400.
Li XR, Kruchko C, Wu XC, et al. Are benign and borderline brain tumors underreported? J Registry Manag. 2016;43:187-194.
Braganza MZ, Kitahara CM, Berrington de Gonzalez A, Inskip PD, Johnson KJ, Rajaraman P. Ionizing radiation and the risk of brain and central nervous system tumors: a systematic review. Neuro Oncol. 2012;14:1316-1324.
Davis F, Il'yasova D, Rankin K, McCarthy B, Bigner DD. Medical diagnostic radiation exposures and risk of gliomas. Radiat Res. 2011;175:790-796.
Wrensch M, Lee M, Miike R, et al. Familial and personal medical history of cancer and nervous system conditions among adults with glioma and controls. Am J Epidemiol. 1997;145:581-593.
Rice T, Lachance DH, Molinaro AM, et al. Understanding inherited genetic risk of adult glioma-a review. Neurooncol Pract. 2016;3:10-16.
Wigertz A, Lonn S, Schwartzbaum J, et al. Allergic conditions and brain tumor risk. Am J Epidemiol. 2007;166:941-950.
Ostrom QT, Cote DJ, Ascha M, Kruchko C, Barnholtz-Sloan JS. Adult glioma incidence and survival by race or ethnicity in the United States From 2000 to 2014. JAMA Oncol. 2018;4:1254-1262.
Ostrom QT, Rubin JB, Lathia JD, Berens ME, Barnholtz-Sloan JS. Females have the survival advantage in glioblastoma. Neuro Oncol. 2018;20:576-577.
Achey RL, Gittleman H, Schroer J, Khanna V, Kruchko C, Barnholtz-Sloan JS. Nonmalignant and malignant meningioma incidence and survival in the elderly, 2005-2015, using the Central Brain Tumor Registry of the United States. Neuro Oncol. 2019;21:380-391.
Cahill KS, Claus EB. Treatment and survival of patients with nonmalignant intracranial meningioma: results from the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute. Clinical article. J Neurosurg. 2011;115:259-267.
Varlamov EV, McCartney S, Fleseriu M. Functioning pituitary adenomas-current treatment options and emerging medical therapies. Eur Endocrinol. 2019;15:30-40.
Worrell SL, Kirschner ML, Shatz RS, Sengupta S, Erickson MG. Interdisciplinary approaches to survivorship with a focus on the low-grade and benign brain tumor populations. Curr Oncol Rep. 2021;23:19.
Adel Fahmideh M, Scheurer ME. Pediatric brain tumors: descriptive epidemiology, risk factors, and future directions. Cancer Epidemiol Biomarkers Prev. 2021;30:813-821.
Ostrom QT, Chen Y, de Blank PM, et al. The descriptive epidemiology of atypical teratoid/rhabdoid tumors in the United States, 2001-2010. Neuro Oncol. 2014;16:1392-1399.
Siegel DA, Li J, Ding H, Singh SD, King JB, Pollack LA. Racial and ethnic differences in survival of pediatric patients with brain and central nervous system cancer in the United States. Pediatr Blood Cancer. 2019;66:e27501.
Mitchell HK, Morris M, Ellis L, Abrahao R, Bonaventure A. Racial/ethnic and socioeconomic survival disparities for children and adolescents with central nervous system tumours in the United States, 2000-2015. Cancer Epidemiol. 2020;64:101644.
Oyefiade A, Paltin I, De Luca CR, et al. Cognitive risk in survivors of pediatric brain tumors. J Clin Oncol. 2021;39:1718-1726.
Padovani L, Andre N, Constine LS, Muracciole X. Neurocognitive function after radiotherapy for paediatric brain tumours. Nat Rev Neurol. 2012;8:578-588.
Turner CD, Rey-Casserly C, Liptak CC, Chordas C. Late effects of therapy for pediatric brain tumor survivors. J Child Neurol. 2009;24:1455-1463.
Gurney JG, Kadan-Lottick NS, Packer RJ, et al. Endocrine and cardiovascular late effects among adult survivors of childhood brain tumors: Childhood Cancer Survivor Study. Cancer. 2003;97:663-673.
van Schaik J, van Roessel IMAA, Schouten-van Meeteren NAYN, et al. High prevalence of weight gain in childhood brain tumor survivors and its association with hypothalamic-pituitary dysfunction. J Clin Oncol. 2021;39:1264-1273.
Zebrack BJ, Gurney JG, Oeffinger K, et al. Psychological outcomes in long-term survivors of childhood brain cancer: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2004;22:999-1006.
Ris MD, Leisenring WM, Goodman P, et al. Neuropsychological and socioeconomic outcomes in adult survivors of pediatric low-grade glioma. Cancer. 2019;125:3050-3058.
Gurney JG, Krull KR, Kadan-Lottick N, et al. Social outcomes in the Childhood Cancer Survivor Study cohort. J Clin Oncol. 2009;27:2390-2395.